EXPRESSION AND LOCALIZATION
===========================

Calcium/calmodulin dependent protein kinase II (CaMKII) is a multimeric enzyme consisting of distinct subunits encoded by four different genes known as CaMKIIα, β, γ, and δ. These genes have a high degree of sequence homology but show differential tissue expression. CaMKIIα and β are predominantly expressed in neuronal tissue while γ and δ are present throughout the body, including the heart ([@B4]; [@B43]). CaMKIIδ is the predominant cardiac isoform and is alternatively spliced to generate multiple subtypes ([@B7]).

[@B40] were the first to demonstrate that there are different subtypes of CaMKIIδ expressed in various tissues. The authors reported four distinct proteins with differential expression patterns and named them CaMKIIδ~1-4~. CaMKIIδ~2~, and CaMKIIδ~3~ were shown to be identical except for the insertion of an 11-amino acid sequence in the variable domain of CaMKIIδ~3~, the more abundant of the two subtypes in the heart ([@B40]). Around the same time, [@B7] identified these same CaMKIIδ subtypes in rat heart and characterized their catalytic activity and regulation by calcium-liganded calmodulin (Ca^2+^/CaM). They refer to the predominant cardiac subtypes as CaMKIIδ~B~ and CaMKIIδ~C~ (the convention that will be used in this review), which correspond to the δ~3~ and δ~2~ subtypes, respectively. The structure of these proteins is shown in **Figure [1](#F1){ref-type="fig"}**. CaMKIIδ~B~ and δ~C~ possess similar catalytic activity and sensitivity to Ca^2+^/CaM. Furthermore, both subtypes can undergo autophosphorylation and acquire a similar degree of Ca^2+^-independent or autonomous activity ([@B7]). In the years that followed, seven additional splice variants of the CaMKIIδ gene, referred to as CaMKIIδ~5-11~, were identified. Only one of these, CaMKIIδ~9~, is expressed in the adult heart (**Figure [1](#F1){ref-type="fig"}**; [@B33], [@B32]; [@B13], [@B14]).

![**Domain scheme of CaMKIIδ monomers.** The four subtypes shown are distinguished by the amino acid sequence of a variable region between the regulatory and association domains. CaMKIIδ~2/C~ lacks this variable domain while CaMKIIδ~3/B~ contains an 11-amino acid insertion that contains the canonical nuclear localization signal (NLS) sequence KKRK. An asterisk denotes a phosphorylation site (Ser^332^) in this domain that affects NLS accessibility. CaMKIIδ~9~ contains a different variable domain sequence that is also present in the longer variable region of CaMKIIδ~1/A~. All of these subtypes can be detected in adult murine heart with the exception of CaMKIIδ~1/A~, which is normally only present in neonatal mouse heart.](fphar-05-00015-g001){#F1}

The 11-amino acid insert in CaMKIIδ~B~ (^328^KKRKSSSSVQMM) is also present in some splice variants of CaMKIIα and γ; this conservation suggests an important function ([@B40]). [@B42] showed that when constructs of CaMKIIδ~B~ are transfected into fibroblasts the expressed protein is localized to the nucleus. This is not the case for constructs of CaMKIIδ~C~, implying that that the additional amino acid sequence present in CaMKIIδ~B~ is responsible for nuclear localization ([@B42]). A similar differential localization pattern was also observed when CaMKIIδ subtypes were expressed neonatal rat ventricular myocytes (NRVMs; [@B37]). Further studies showed that the 11-amino acid insert in CaMKIIδ~B~ can confer nuclear localization when inserted into the variable domain of CaMKIIα and that mutagenesis of the first two lysines in the insert abrogates the nuclear localization of these constructs. Thus it is widely accepted that the CaMKIIδ~B~ variable domain contains a nuclear localization signal (NLS).

CaMKII heteromultimerization is permissive in that the CaMKII holoenzyme can include subunits from multiple CaMKII genes and multiple splice variants of those genes ([@B4]; [@B51]). It seems likely that more than a single CaMKIIδ subtype is present in a single CaMKIIδ multimer and accordingly the ratio of δ~B~ to δ~C~ in a multimer could regulate the localization of the holoenzyme. This has been demonstrated experimentally. When CaMKIIδ~B~ and δ~C~ are cotransfected into fibroblasts or NRVMs, the localization of the expressed protein can be shifted in accordance with the ratio of the expressed CaMKIIδ subtypes, i.e., highly expressed δ~C~ sequesters δ~B~ in the cytosol and blocks its nuclear localization ([@B42]; [@B37]). The opposite is also true: high relative expression of δ~B~ can localize δ~C~ to the nucleus. While not well appreciated, CaMKIIδ~B~ localization can also be regulated by phosphorylation. A serine (Ser^332^) immediately adjacent to the NLS of CaMKIIδ~B~ was shown to be a site of phosphorylation by CaMKI and CaMKIV *in vitro*. Phosphorylation prevents association of δ~B~ with the NLS receptor m-pendulin and thus limits localization of CaMKIIδ~B~ to the nucleus ([@B12]). Remarkably this mode of regulation is also seen when the NLS is moved from the middle of the protein to the N-terminus, suggesting that conformational changes are not required for phosphorylation to block the NLS.

Relative expression of CaMKIIδ subtypes is altered during cardiomyocyte differentiation and maturation and in association with the development of heart failure and ischemia/reperfusion (I/R) injury ([@B13], [@B14]; [@B5]; [@B36]). In humans CaMKIIδ~B~ mRNA is selectively upregulated during heart failure ([@B14]). The altered expression of particular subtypes suggests the possibility of a regulated process governing CaMKIIδ mRNA splicing because transcriptional regulation would not be expected to alter the ratio of CaMKIIδ subtypes. Alternative splicing factor/pre-mRNA-splicing factor SF2 (ASF/SF2) was initially described by [@B22] and subsequently mice lacking ASF/SF2 expression were demonstrated to have incomplete processing of CaMKIIδ mRNA ([@B22]; [@B50]). Specifically, enhanced expression of the δ~A~ subtype \[δ~1~ in the nomenclature of [@B40]\] was observed while expression of CaMKIIδ~B~ and δ~C~ was diminished. **Figure [1](#F1){ref-type="fig"}** also depicts the structure of the δ~A~ subtype, which is expressed in the fetal heart. ASF/SF2 can be regulated by phosphorylation. Protein kinase A (PKA)-mediated ASF/SF2 phosphorylation has been correlated with alternative splicing of CaMKIIδ in heart and brain ([@B9]). Additionally, regulation of ASF/SF2 by Protein phosphatase 1 γ (PP1γ) has been demonstrated to affect CaMKIIδ splicing ([@B15]). CaMKIIδ~A~ expression is increased in models of isoproterenol-induced cardiac hypertrophy and thus regulation of CaMKIIδ splicing by PKA and PP1γ may be relevant in the context of chronic β-adrenergic stimulation ([@B23]). The RNA binding proteins Fox 1 (RBFOX1) and 2 (RBFOX2) collaborate with ASF/SF2 to induce proper CaMKIIδ splicing ([@B11]) and factors that regulate these proteins could also influence the expression of CaMKIIδ subtypes. Thus, CaMKIIδ splicing is a dynamic and regulated process. The role of this system in the heart has not been extensively explored but could be of major importance since regulation of CaMKIIδ splicing may account for altered subtype expression and CaMKIIδ signaling in physiological and pathophysiological settings.

CaMKIIδ~B~ TRANSGENIC MICE
==========================

The differential localization and function of CaMKIIδ subtypes could be of considerable importance to understanding the role of this enzyme in normal physiology and disease states. Early studies demonstrated that expression of CaMKIIδ~B~ in NRVMs induced atrial natriuretic factor (ANF) expression and led to increased myofilament organization, both hallmarks of cardiac hypertrophy, while expression of CaMKIIδ~C~ did not ([@B37]). This finding suggested that nuclear CaMKIIδ localization is required to regulate gene expression. Consistent with this notion are data indicating that CaMKIIδ~B~ signaling activates several transcription factors including myocyte enhancer factor 2 (MEF2), GATA4, and heat shock factor 1 (HSF1; [@B26]; [@B28]; [@B36]). The significance of the hypertrophic responses elicited by δ~B~ *in vitro* was explored further by generation of CaMKIIδ~B~ transgenic (TG) mice ([@B53]). These animals, which overexpress δ~B~ under the control of the cardiac-specific α-myosin heavy chain (α-MHC) promoter, demonstrate the enhanced expression of hypertrophic markers observed in NRVMs expressing CaMKIIδ~B~. CaMKIIδ~B~TG animals develop hypertrophy and moderate cardiac dysfunction by 4 months of age. Thus, CaMKIIδ~B~ expression appears to be sufficient to induce cardiac hypertrophy. Surprisingly, despite the increased CaMKII activity in the CaMKIIδ~B~TG mouse heart, phosphorylation of the canonical cardiac CaMKII substrate phospholamban (PLN) at its CaMKII site (Thr^17^) was not increased but rather was decreased relative to WT mice. PLN phosphorylation at the PKA site (Ser^16^) was similarly reduced. These data were related to increases in phosphatase activity ([@B53]), but also implied that CaMKIIδ~B~ did not lead to robust phosphorylation of PLN. A subsequent paper that examined CaMKIIδ~B~TG animals at a younger age to avoid changes in phosphatase activity confirmed that phosphorylation of PLN and another cardiac CaMKII substrate, the cardiac ryanodine receptor (RyR2), was not increased by cardiac CaMKIIδ~B~ expression ([@B54]). This finding is consistent with a predominantly nuclear localization and function of the δ~B~ subtype.

CaMKIIδ~B~ has also been suggested to regulate expression of the Na^+^/Ca^2+^ exchanger (NCX1) during the development of cardiac dysfunction following trans-aortic constriction (TAC; [@B27]). The conclusion that δ~B~ was the subtype involved in NCX1 regulation relied on the use of a constitutively active construct of CaMKIIδ~B~ in which a Thr to Asp mutation (T287D) simulates autophosphorylation. Interestingly, the authors found that this construct was excluded from the nucleus ([@B28]). This differs from the localization pattern described above ([@B42]; [@B37]) and can be explained as a result of phosphorylation of Ser^332^ in the 11-amino acid insert of δ~B~ (**Figure [1](#F1){ref-type="fig"}**). The observation that mutation of Ser^332^ to Ala restores nuclear localization of constitutively active CaMKIIδ~B~ ([@B3]) confirms the role of this site in the cytosolic localization of the active construct. The possibility that phosphorylation of Ser^332^ might regulate CaMKIIδ~B~ localization in the intact heart has not been evaluated, but such a mechanism could contribute to the observation that CaMKIIδ~B~ is found outside the nucleus even in the absence of multimerization with δ~C~([@B35]).

CaMKIIδ~C~ TRANSGENIC MICE
==========================

CaMKIIδ~C~ transgenic mice have also been generated and demonstrate a strikingly different phenotype from mice that express CaMKIIδ~B~. While cardiac dysfunction is relatively moderate and takes months to develop in CaMKIIδ~B~TG animals, mice expressing δ~C~ rapidly progress to heart failure and premature death ([@B55]). By 6 weeks of age CaMKIIδ~C~TG animals display marked changes in cardiac morphology and by 12 weeks these animals display severe cardiac dysfunction and upregulation of hypertrophic genes.

Ca^2+^ HANDING AND ARRHYTHMIA
-----------------------------

Expression of the cardiac sarco/endoplasmic reticulum Ca^2+^-ATPase (SERCA) is diminished in δ~C~TG mice as occurs in other models of heart failure. Since SERCA regulates Ca^2+^ reuptake into the sarcoplasmic reticulum (SR), this decrease would diminish SR Ca^2+^ loading. On the other hand, the CaMKIIδ~C~TG mice show hyperphosphorylation of PLN at Thr^17^, which should improve SERCA function. In addition δ~C~TG animals display marked increases in phosphorylation of the RyR2, the channel through which Ca^2+^ exits the SR. Taken together, these changes would predict dysregulation of SR Ca^2+^ cycling and excitation--contraction coupling. This was substantiated in an accompanying paper that systematically analyzed and demonstrated dysregulation of cardiac Ca^2+^ handling in mice expressing δ~C~ ([@B30]). Specifically it was shown that SR Ca^2+^ stores were depleted in myocytes from these animals, explaining the observation that isolated myocytes displayed diminished twitch shortening amplitude. Furthermore, [@B30] showed that the frequency and duration of Ca^2+^ sparks, or spontaneous intracellular Ca^2+^-release events, was markedly increased in myocytes from animals expressing δ~C~. Hyperphosphorylation of RyR2 by CaMKIIδ~C~ was hypothesized to underly the enhanced leak of Ca^2+^ from the SR, and this was verified by the demonstration that acute inhibition of CaMKII in δ~C~TG myocytes rescues the altered Ca^2+^ handling ([@B30]). In other experiments, acute expression of δ~C~ in rabbit cardiomyocytes was shown to be sufficient to induce SR Ca^2+^ sparks and diminished SR Ca^2+^ loading ([@B20]). These findings imply that direct regulation of Ca^2+^ handling targets including RyR2 by CaMKIIδ~C~ can account for the dysregulation of Ca^2+^ and contractile function seen in myocytes from δ~C~TG animals (**Figure [2](#F2){ref-type="fig"}**).

![**Localization and function of CaMKIIδ subtypes in the adult cardiomyocyte.** The circles labeled δ~C~ and δ~B~ represent CaMKIIδ multimers that are composed primarily of δ~C~ and δ~B~ subunits, respectively. Documented phosphorylation events are indicated by dashed lines. CaMKIIδ~C~ regulates Ca^2+^ homeostasis and currents involved in arrhythmogenesis through phosphorylation of Ca^2+^ handling proteins and channels. CaMKIIδ~C~ can also affect gene transcription through direct and indirect mechanisms including phosphorylation of NFAT and HDAC (sequestering them in the cytosol), increases in p53, and increased nuclear import of NF-κB. The CaMKIIδ~B~ subtype has little effect on phosphorylation of Ca^2+^ handling proteins but increases gene expression through HDAC phosphorylation and nuclear export and activation of HSF1 and GATA4. A putative mechanism for δ~B~redistribution is depicted, showing δ~B~exiting or being excluded from the nucleus due to phosphorylation at a site (Ser^332^) adjacent to its NLS.](fphar-05-00015-g002){#F2}

Dysregulation of excitation--contraction coupling by CaMKII is thought to contribute to arrythmogenesis in a variety of contexts, as supported by the increased incidence of arrhythmogenic events in CaMKIIδ~C~TG mice ([@B1]; [@B49]; [@B46]). Overexpression of CaMKIIδ~C~ not only induces more spontaneous arrhythmias but also enhances the susceptibility of mice to arrhythmogenic challenge by β-adrenergic stimulation. [@B39] found that much of the proarrhythmogenic effects of β-adrenergic stimulation on SR Ca^2+^ leak were significantly inhibited by treatment of myocytes with KN-93, an inhibitor of CaMKII. Furthermore the SR Ca^2+^ leak induced by isoproterenol did not occur in myocytes from mice lacking CaMKIIδ. These findings collectively implicate SR Ca^2+^ leak as one of the key mechanisms in δ~C~-mediated arrhythmias ([@B39]). The notion that hyperphosphorylation of RyR2 at the CaMKII site (Ser^2814^) contributes to arrhythmias and SR Ca^2+^ leak is supported by the finding that mutation of Ser^2814^ to Ala (S2814A) blocks the ability of CaMKII to induce Ca^2+^ sparks ([@B45]). The autosomal dominant form of catecholaminergic polymorphic ventricular tachycardia (CPVT) can be caused by the RyR2 mutation R4496C and mice carrying this mutation are predisposed to arrhythmia and ventricular fibrillation. Enhanced CaMKIIδ~C~ expression and activity are implicated in the etiology of premature death in CPVT as expression of CaMKIIδ~C~ exacerbates the effects of the R4496C mutation ([@B6]). As mentioned earlier RyR2 Ser^2814^ phosphorylation is increased by expression of CaMKIIδ~C~ (but not by δ~B~) *in vivo* ([@B54]) and the effects of mutating this site ([@B45]) emphasize the importance of RyR2 phosphorylation by CaMKII in SR Ca^2+^ leak and arrhythmia.

Other targets besides those at the SR may contribute to the arrhythmogenic phenotype of CaMKIIδ~C~ mice. The cardiac sodium channel Na~V~1.5 is physically associated with CaMKIIδ~C~ based on coimmunoprecipitation of these proteins from CaMKIIδ~C~TG animals and Na~V~1.5 is phosphorylated in mice expressing δ~C~ ([@B46]). CaMKIIδ~C~ phosphorylates Na~V~1.5 at multiple sites and phosphorylation appears to elicit the loss-of-function changes in Na~V~1.5 gating that are observed in the context of CaMKIIδ~C~ expression *in vitro*([@B2]; [@B21]). Incomplete inactivation of Na~V~1.5 generates a late Na^+^ current (*I*~Na~), which can prolong the duration of the action potential and contribute to arrhythmias. Additionally, increased *I*~Na~ can lead to Na^+^-overloading of the cardiomyocyte, which contributes to diminished diastolic contractile performance ([@B31]). Late *I*~Na~ is observed in CaMKIIδ~C~TG mice and inhibition of this current ameliorates arrhythmia and diastolic dysfunction in these animals ([@B41]). Modulation of *I*~Na~ therefore appears to contribute to the phenotype of CaMKIIδ~C~ mice with respect to arrhythmia development; additionally the CaMKIIδ~C~ subtype likely regulates the L-type Ca^2+^ channel (LTCC) and repolarizing potassium currents (*I*~to~ and *I*~K1~; [@B34]; [@B47]). Thus, a multitude of mechanisms link CaMKIIδ~C~ to arrhythmogenesis.

CONTRACTILE DYSFUNCTION
-----------------------

Arrhythmias may contribute to the premature death of CaMKIIδ~C~TG mice but there are also marked decreases in contractile function in these animals. Since alterations to cardiomyocyte Ca^2+^ handling are seen in relatively young CaMKIIδ~C~TG mice and precede the development of heart failure, it is possible that dysregulated Ca^2+^ homeostasis (specifically SR Ca^2+^ leak) is an initiating event in δ~C~-induced heart failure. Specifically, as a consequence of SR Ca^2+^ leak and SERCA downregulation, the SR Ca^2+^ load is diminished which would compromise contractile function. To determine whether diminished SR Ca^2+^ load is the primary causal event leading to contractile dysfunction and premature death in response to δ~C~ overexpression, we crossed the δ~C~TG mice with mice in which the SERCA regulatory protein PLN was deleted (PLN-KO). Deletion of PLN in the context of δ~C~ overexpression normalized SR Ca^2+^ levels and the contractile function of isolated myocytes was restored ([@B52]). Remarkably the development of cardiac dysfunction *in vivo* was not rescued but instead was accelerated in the δ~C~TG/PLN-KO mice. In addition SR Ca^2+^ leak was enhanced. It was hypothesized that the increased SR Ca^2+^ load, in the context of RyR2 hyperphosphorylation, precipitated greater Ca^2+^ leak and further suggested that the accelerated development of cardiac dysfunction was due to mitochondrial Ca^2+^ overloading ([@B52]). These observations and their interpretation places central importance on the Ca^2+^ leak elicited by δ~C~-mediated phosphorylation of RyR2 in the development of heart failure. Further support for this hypothesis comes from the finding that CaMKIIδ knockout mice have attenuated contractile dysfunction in response to pressure overload induced by TAC and myocytes from these animals show diminished SR Ca^2+^ leak in response to TAC ([@B25]). Additionally, mice expressing the RyR2 S2814A mutation are protected from the development of heart failure in response to pressure overload ([@B38]) consistent with a critical role for CaMKII-mediated RyR2 phosphorylation. We recently crossed CaMKIIδ~C~ mice with those expressing RyR2 S2814A; if the hypothesis is correct these mice will show diminished SR Ca^2+^ leak and improved contractile function when compared to CaMKIIδ~C~TG mice.

Another approach used to determine the role of RyR2 phosphorylation and SR Ca^2+^ leak in the phenotype of CaMKIIδ~C~TG mice was to cross the CaMKIIδ~C~TG mice with mice expressing SR-targeted autocamtide-2-related inhibitory peptide (SR-AIP; [@B16]). AIP simulates the regulatory domain of CaMKII and inhibits the kinase, and SR-AIP mice have been shown to display diminished phosphorylation of CaMKII substrates at the SR ([@B17]). A reduction in the extent of PLN and RyR2 hyperphosphorylation observed in CaMKIIδ~C~TG mice was conferred by SR-AIP. There were associated changes in Ca^2+^ handling that indicated a modest improvement in SR Ca^2+^ leak. Despite the salutary effects of SR-AIP in cells from δ~C~TG mice, *in vivo* cardiac function was not improved. One possible explanation for these findings is that the degree of inhibition of RyR2 phosphorylation conferred by SR-AIP was insufficient to prevent the effects of CaMKIIδ~C~ overexpression. Alternatively, while δ~C~-mediated phosphorylation of targets at the SR including RyR2 and PLN is of considerable consequence, targets of CaMKII elsewhere in the cell may also contribute to the pathogenesis of cardiac dysfunction induced by CaMKIIδ~C~.

Mitochondrial Ca^2+^ is elevated in mice overexpressing δ~C~ in the context of intact SR Ca^2+^ load ([@B52]) and increases in mitochondrial Ca^2+^ are known to induce opening of the mitochondrial permeability transition pore (MPTP) and cell death ([@B10]). Considering the central importance of mitochondria in the regulation of cell death and of cell death in the development of heart failure ([@B48]), any pathway by which CaMKIIδ~C~ induces mitochondrial Ca^2+^ overloading and subsequent loss of mitochondrial integrity would be predicted to contribute to the development of contractile dysfunction and heart failure. To test the role of mitochondrial dysregulation in the cardiomyopathy that develops in δ~C~TG animals, CaMKIIδ~C~TG mice were crossed with mice lacking expression of cyclophilin D, a mitochondrial protein required for the formation of the MPTP. The ability of high Ca^2+^ to induce swelling of isolated mitochondria, an index of MPTP opening, was impaired in the CaMKIIδ~C~TG mice lacking cyclophilin D, but development of dilated cardiomyopathy and premature death of these mice was not diminished. Indeed these responses were exacerbated when compared to δ~C~TG mice with intact cyclophilin D expression. The authors suggest that cyclophilin D may actually play a beneficial role in stress responses, as they observed that TAC-induced heart failure development was also made more severe by genetic deletion of cyclophilin D ([@B8]). However, CaMKIIδ~C~ is found at mitochondria and a recent seminal study by [@B19] identified the mitochondrial Ca^2+^ uniporter (MCU) as a potential target of CaMKII ([@B35]; [@B19]). While phosphorylation of the MCU by CaMKII was not shown to occur *in vivo*, a CaMKII-dependent change in the function of the MCU was evidenced by data demonstrating that a CaMKII inhibitory peptide targeted to the mitochondria diminished mitochondrial Ca^2+^ uptake and inhibited apoptosis in mice subjected to myocardial infarction and I/R injury.

CaMKIIδ SUBTYPES IN GENE TRANSCRIPTION
======================================

The discussion above, and indeed most of the literature, considers the role of CaMKIIδ-mediated phosphorylation and regulation of Ca^2+^ handling proteins and ion channels. Chronic elevations in CaMKIIδ expression and activity are observed in humans with heart failure ([@B14]) and these long-term changes are likely to elicit altered gene expression. As discussed earlier, CaMKIIδ~B~ induces the expression of hypertrophic genes in myocytes and transgenic mice, consistent with its primarily nuclear localization ([@B37]; [@B53]). Other work showed that the CaMKIIδ~B~ subtype is required for GATA-4 binding to the B cell lymphoma 2 (Bcl-2) promoter and subsequent gene expression ([@B26]). Furthermore, CaMKIIδ~B~ was shown to phosphorylate the transcription factor HSF1 thereby increasing its transcriptional activity ([@B36]). Taken together, these observations imply that it is the CaMKIIδ~B~ subtype that regulates gene expression as a result of its actions in the nucleus.

It is not necessarily the case, however, that gene regulation requires CaMKIIδ to be localized to the nuclear compartment. Despite its primarily cytosolic localization, CaMKIIδ~C~ overexpressed in mouse heart increased phosphorylation of histone deacetylase 4 (HDAC4), resulting in activation of the transcription factor MEF2 ([@B54]). CaMKIIδ~C~ has also been demonstrated to regulate nuclear localization of nuclear factor of activated T cells (NFATs) in NRVM. The ability of CaMKIIδ~C~ to decrease nuclear NFAT was blocked by coexpression of a dominant-negative construct of CaMKIIδ~C~ and was shown to be elicited by phosphorylation and inhibition of the Ca^2+^/CaM dependent phosphatase calcineurin (Cn; [@B29]), presumably in the cytosol. Alteration of Ca^2+^ homeostasis by cytosolic CaMKIIδ~C~ expression may indirectly affect gene expression and additionally the constitutively active CaMKIIδ~B~ utilized in the studies discussed above ([@B27]) is cytosolic and yet regulates expression of NCX1.

Regulation of gene expression by CaMKIIδ~B~ has been demonstrated to promote cardiomyocyte survival while the opposite is true for CaMKIIδ~C~. CaMKIIδ~B~ was shown to protect cardiomyocytes from doxorubicin-induced cell death via transcriptional upregulation of Bcl-2 ([@B26]). Along similar lines, CaMKIIδ~B~ contributes to cardioprotection from H~2~O~2~ by increasing inducible heat shock protein 70 (iHSP70) expression ([@B36]). Conversely, CaMKIIδ~C~ activation is implicated in cell death elicited by a variety of stimuli ([@B56]). It has been suggested that CaMKIIδ~C~ (but not δ~B~) upregulates the proapoptotic transcription factor p53 ([@B44]), and recent work from our laboratory demonstrates that CaMKIIδ~C~ expression in NRVMs activates the proinflammatory transcription factor nuclear factor κB (NF-κB; [@B24]). We demonstrated that CaMKIIδ~C~ increased phosphorylation of IκB Kinase (IKK) and since IKK activation can also upregulate p53([@B18]), this pathway may contribute to the proapoptotic response reported by [@B44].

FUTURE DIRECTIONS
=================

There is compelling evidence that the CaMKIIδ~B~ and δ~C~ subtypes differentially regulate cardiomyocyte Ca^2+^ handling and survival *in vitro*. Whether this occurs *in vivo* under physiological or pathophysiological conditions, and whether δ~B~ and δ~C~ subserve different functions based on their localization or selective activation, remains to be determined.

It seems likely that the relative levels of endogenous δ~B~ and δ~C~ determine localization and could therefore impact CaMKIIδ signaling. Hypothetically, a selective increase in CaMKIIδ~C~ would result in accumulation of cytosolic CaMKIIδ and depletion of nuclear CaMKIIδ while a selective increase in CaMKIIδ~B~ would have the opposite effect. CaMKIIδ redistribution in this manner may contribute to the phenotype of mice that overexpress δ~B~ and δ~C~ and importantly there are changes in the relative expression of δ~B~ and δ~C~ in models of heart failure and I/R injury. In both models δ~C~ expression is enhanced relative to that of δ~B~ ([@B55]; [@B36]). It is not known how this occurs but it is of interest to postulate that in heart failure and during I/R regulation of CaMKIIδ splicing is altered. ASF/SF2 and RBFOX1/2 regulate the splicing of the CaMKIIδ gene and thus expression of δ~B~ and δ~C~, but whether changes in splicing occur in and contribute to the development of heart failure or I/R injury remains to be determined. It is likely that the increased δ~C~ expression observed in these models is pathogenic.

While CaMKIIδ~B~ contains an NLS, this subtype is not completely sequestered in the nucleus ([@B35]). As mentioned previously the NLS within the variable domain of δ~B~ can be regulated by phosphorylation, which prevents nuclear localization. This type of regulation could be of considerable importance since the nuclear localization of δ~B~ appears to correlate with enhanced expression of protective genes and cell survival while cytosolic localization does not ([@B26]; [@B36]; [@B27]).

Of additional interest is the neglected CaMKIIδ~9~. The pioneering work of ([@B13]; [@B32]) identified δ~9~ as one of the three subtypes of CaMKIIδ in the adult heart and showed that it is expressed at similar levels to those of CaMKIIδ~B~. δ~9~ contains a sequence (^328^EPQTTVIHNPDGNK) not present in δ~B~ or δ~C~ and thus may possess unique properties that merit further investigation, as the function and localization of δ~9~ *in vivo* has not been explored. Along similar lines, CaMKIIδ~A~ expression is increased in a model of cardiac hypertrophy ([@B23]), but the possibility that this splice variant is upregulated in and contributes to cardiovascular disease has not been investigated.
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